OBJECTIVE: To investigate the characteristics of clinical application of sodium tanshinone Ⅱ

A

sulfonate injection in treatment of cerebral infarction in the real world

so as to provide references for standardizing clinical medication. METHODS: Based on the hospital information system in Kunshan Hospital of traditional Chinese Medicine

hospitalized cases of 545 patients with cerebral infarction who treated with sodium tanshinone Ⅱ

A

sulfonate injection from 2016 to 2017 were collected and analyzed in terms of patients ’ general information

medication characteristics and drug combination

etc. RESULTS: Of the 545 patients with cerebral infarction who treated with sodium tanshinone Ⅱ

A

sulfonate injection

279 cases were male（ 51. 19%）

266 were female（ 48. 81%）

with similar proportion; the average age was 66. 84 years old

and most of patients were aged over 45 to 80 years old（ 409 cases

75. 05%）; all the patients were administered by intravenous drip

with the single dose was mainly 60 mg（ 463 cases

84. 95%）; the treatment course was mainly 1 to 14 days（ 508 cases

93. 21%）

with an average of（ 7. 15± 4. 71） d; the drugs used in combination with sodium tanshinone Ⅱ

A

sulfonate injection mainly involving Omeprazole capsules

alprostadil injections

clopidogrel hydrogen tablets

Atorvastatin calcium tablets

Rosuvastatin calcium tablets and lipoic acid injection. CONCLUSIONS: The middle-aged and elderly people are the main population for the occurrence of cerebral infarction

the application of sodium tanshinone Ⅱ

A

sulfonate injection is often in combination with anti-platelet aggregation drugs and lipid-regulating drugs

although it conforms to the medication specifications

there are also problems such as over-concentration medications

which should be paid attention.